Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1TT
|
|||
| Former ID |
DIB011047
|
|||
| Drug Name |
AdCh63-MSP1
|
|||
| Synonyms |
MVA-MSP1; MSP1 prime-boost vaccine (Plasmodium infection); MSP1 prime-boost vaccine (Plasmodium infection), University of Oxford
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Malaria [ICD-11: 1F40-1F45; ICD-10: B50-B64, B54] | Phase 1/2 | [1] | |
| Company |
University of Oxford
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasmodium Merozoite surface protein 1 (Malaria MSP-1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health. | |||
| REF 2 | Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014 Apr;141(4):628-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.